Newtyn Management’s Olema Pharmaceuticals OLMA Stock Holding History

Newtyn Management’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-140,000	Closed	-$816K	–	33
2024 Q4	$816K	Hold	140,000	–	–	0.14%	32
2024 Q3	$1.67M	Hold	140,000	–	–	0.26%	35
2024 Q2	$1.51M	Sell	140,000 -10,000	-7%	-$108K	0.28%	33
2024 Q1	$1.7M	Hold	150,000	–	–	0.34%	32
2023 Q4	$2.1M	Hold	150,000	–	–	0.41%	32
2023 Q3	$1.85M	Sell	150,000 -25,000	-14%	-$255K	0.46%	32
2023 Q2	$1.58M	Sell	175,000 -200,000	-53%	-$1.21M	0.37%	34
2023 Q1	$1.3M	Buy	375,000 +15,000	+4%	+$61.2K	0.26%	54
2022 Q4	$882K	Sell	360,000 -40,000	-10%	-$117K	0.18%	56
2022 Q3	$1.1M	Sell	400,000 -100,000	-20%	-$424K	0.24%	49
2022 Q2	$2.04M	Buy	+500,000	New	+$1.59M	0.39%	40

Other funds holding OLMA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LMC

Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return

Newtyn Management's OLMA Position: Q1 2025 in Review

Newtyn Management sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 140,000 shares — an estimated $816K sold.

Newtyn Management first reported a position in OLMA in Q2 2022 and held it in 11 quarters. The position peaked at $2.1M in Q4 2023. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

Newtyn Management reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Newtyn Management sold 140,000 Olema Pharmaceuticals shares in Q1 2025, an estimated $816K.
Newtyn Management first reported a position in Olema Pharmaceuticals in Q2 2022 and held it in 11 quarters.
Newtyn Management's Olema Pharmaceuticals position peaked at $2.1M in Q4 2023.
133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on Newtyn Management's 13F filing for Q1 2025, filed 15 May 2025.